Navigation Links
Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimer's Disease
Date:9/4/2012

ALISO VIEJO, Calif., Sept. 4, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

"Alzheimer's disease can cause a person to exhibit marked behavioral changes that are difficult for caregivers to manage. These symptoms can include agitation, hostility, anger, and aggression, with most patients exhibiting some or all of these symptoms during the course of the disease," said Jeffrey Cummings, MD, Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic. "As the disease progresses, behavioral symptoms often increase in frequency and severity. With no approved therapies for agitation associated with dementia, managing these symptoms can be challenging. This trial is an important initial step in potentially providing a therapy to help manage symptoms of agitation in Alzheimer's disease."

The objectives of this proof of concept study are to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of agitation in Alzheimer's patients. The trial is a multicenter, randomized, double-blind, placebo-controlled study that is expected to enroll up to 200 Alzheimer's patients in the United States. Eligible patients will be randomized to receive either AVP-923 or placebo for 10 weeks. The main efficacy measure is the Neuropsychiatric Inventory or NPI. Secondary outcome measures include assessments of disease severity, behavioral abnormalities, cognition, activities of daily living, quality of life and caregiver strain. Standard safety assessments will also be conducted.

Jeffrey Cummings, MD is a paid consultant of Avanir Pharmaceuticals, Inc. In addition, Dr. Cummings is the inventor of the
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present at Three Conferences In May
6. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
7. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
8. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
9. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 China,s ... earthshaking changes. The country,s new leaders have recognized that ... reagents are far from perfect along with rapid population ... Chinese state council issued the latest "Regulations for the ... 2014, and it has come into force as June ...
(Date:9/29/2014)... and PARIS , Sept. 30, 2014 ... (EURONEXT: SAN and NYSE: SNY) today announced that a ... that blocks IL-4 and IL-13 signaling, met all primary ... with nasal polyps (CSwNP) who did not respond to ... potential of dupilumab for use in the treatment of ...
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014  TNI ... biotechnology company pioneering the manufacturing both US and Internationally ... cancer, HIV/AIDS, opportunistic infections and autoimmune diseases in emerging ... Noreen Griffin The letter follows: Dear Shareholders, ... received a number of calls from shareholders and wants ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 9, 2011 The "Scientific Oktoberfest" will be ... distinguished researchers in the field of Chemical Biology. The so-called ... from the 15 th to the 16 th ... (LMU) München. At the two-day conference, 400 researchers ...
... Holdings, Inc., (NYSE: HRC ) today announced ... Item SA and Liko Care AG, the distribution companies ... Switzerland.  Hill-Rom, the global leader in patient support solutions, ... acquisition of Liko, A.B., a leading provider of patient ...
Cached Medicine Technology:"Scientific Oktoberfest" Draws the Worldwide Leading Researchers in the Field of Chemical Biology to Munich 2Hill-Rom Acquires Liko France and Switzerland 2Hill-Rom Acquires Liko France and Switzerland 3
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 From ... will be exhibiting at the 2014 SHSMD Connections Annual ... Society for Healthcare Strategy & Market Development (SHSMD) is ... healthcare marketing, public relations and communications, and strategic planning ... , About SHSMD Connections , The conference is a ...
(Date:9/30/2014)... placebo did not reduce hospital length of stay, intensive ... the risk of death at 6 months among patients ... to a study published in JAMA . The ... its presentation at the European Society of Intensive Care ... low vitamin D levels has been confirmed in patients ...
(Date:9/30/2014)... New Albany, IN (PRWEB) September 30, 2014 ... Dr. Ron Receveur encourages all persons who have ... gum disease in a recent blog post. , The ... reminds those with dental implants that if they don’t ... in the same way people lose their natural teeth: ...
(Date:9/30/2014)... 2014 Youth Town’s annual BBQ/Music Festival ... to 2 p.m. at the Youth Town campus (3641 ... sponsors this family-oriented festival, which will offer music, food ... feature a car show, arts and crafts fair, music, ... games. Also, Lightning McQueen and Mater from the hit ...
(Date:9/30/2014)... September 30, 2014 “Biology and ... Bryan W. Brickner, “and it’s about naming rights.” ... Science , new on the Bryan William Brickner ... the National Institutes of Health (PubMed). The post ... sleep disturbances, REM transitions, aging with THC, the ...
Breaking Medicine News(10 mins):Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... men and women who engage in high levels of ... knees and increasing their risk for osteoarthritis, according to ... the Radiological Society of North America (RSNA). "Our ... may be at greater risk for developing knee abnormalities ...
... Medical Center researchers have found that informed adults can ... findings, available online and in the December issue of ... caregivers of asthmatic children who have received specialized ... emergency room visits and missed adult workdays. "Childhood ...
... , ... of General Dentistry (AGD) announces that Aria Irvani, DDS, of Orange county CA, received ... excellence in dental education.,To accomplish this, Dr. Irvani completed 1,100 hours of approved continuing ... skills and techniques. , ...
... for something leads to more self-defensive finger pointing, study finds ... is a contagious one, a new study reports, even when ... see someone blame someone else for a problem, even if ... in blaming others, too. , "When we see others ...
... ... for viable affordable alternative care. Affordable Acupuncture Scottsdale answers the call. , ... (PRWEB) November 29, 2009 -- ... been met with enthusiasm and gratitude. Its increasing popularity and rapid success can be ...
... affect circadian rhythm, , FRIDAY, Nov. 27 (HealthDay News) -- ... on the fritz could be a factor in the development ... from the examination of the genetic makeup of 152 children ... mood swings, and 140 children without the disorder. They linked ...
Cached Medicine News:Health News:Too much physical activity may lead to arthritis 2Health News:Parent mentors can improve the asthmatic care of minority children, UT Southwestern researchers find 2Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Bipolar Disorder May Be Tied to Body Clock 2
... the new large power line ... function as both cordless AND ... in flexibility. Its the versatility ... with the security of the ...
... is a full-function, electric powered system ... a wide range of surgical applications ... Bone Orthopedics, Orthopedic Trauma, Oral and ... Surgery. Because it is a complete, ...
The 7500 Drill/Reamer operates at two speeds for multiple applications, which is automatically controlled by the 16 different coupler attachments. The drill reamer can be used for, but is not limited...
... Surgical's Breakthrough in Battery Powered Orthopedic Systems., ... revolutionary new addition to the Hall® Surgical ... Battery System is the first and only ... the market. It is a full-function orthopedic ...
Medicine Products: